Autologous tumor infiltrating lymphocytes (Wuhan Elongevity Technology)

自体肿瘤浸润淋巴细胞 (武汉长生科技)

Report date: 2026/04/17 10:36:23

Base Information

Drug NameAutologous tumor infiltrating lymphocytes (Wuhan Elongevity Technology)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesWuhan Elongevity Technology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesWuhan Elongevity Technology Co Ltd

Inactive CompaniesN/A

Active IndicationsLiver Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A